Breaking limitations of conventional models to accelerate clinical translation of novel tumor immunology drugs – Humanized target models empower precise efficacy evaluation.

1、Service Overview

• In tumor immunology drug discovery, traditional animal models fail to fully recapitulate the human immune microenvironment, resulting in a disconnect between preclinical data and clinical outcomes and high attrition rates in drug development.
• Jennio Bio provides humanized tumor immune target models. At Jennio, highly humanized models are developed via human immune cell engraftment or gene editing, which accurately recapitulate human tumor-immune crosstalk, markedly improve the predictive power of drug efficacy, shorten development cycles, and reduce the risk of clinical failure.

2、Our Services

Humanized Model Development

• Immune System Humanization: Human PBMCs or CD34+ hematopoietic stem cells are implanted into immunodeficient mice to establish humanized immune systems (e.g., NCGhCD34+ model), which are used for the efficacy evaluation of immune checkpoint inhibitors (PD1/PDL1, CTLA4, etc.).
• Target Gene Editing:
• CRISPR Cas9 technology is applied to generate humanized target mice (e.g., hPD 1 knock in model). These models maintain intact mouse immune function while expressing human targets, and are suitable for evaluating bispecific antibodies, CAR T therapies, and other treatments.

Application Scenarios for Efficacy Evaluation

• Immune Checkpoint Inhibitors: Evaluate tumor inhibition rate, immune cell infiltration, and dynamic changes in cytokines for monotherapy and combination regimens.
• Cell Therapy: Monitor in vivo expansion, tumor killing, and toxic reactions (e.g., cytokine release syndrome) of CAR T/TCR T cells.
• Cancer Vaccines: Quantify antigen specific T cell responses and long term immune memory (e.g., IFN γ secretion detected by ELISPOT).

3、Technology Platforms and Advantages

Technology Platform

• Third-generation immunodeficient mouse platform: BRGSF HIS mice, huHSC C NCG mice, etc. It supports the development of humanized models with high human cell chimerism, and the successful model establishment rate is >85%.
• In vivo imaging system: Real-time monitoring of tumor growth and immune cell migration (e.g., dual tracing of fluorescence-labeled tumor cells and human T cells).

Differentiated Advantages

• High clinical relevance: PDX models combined with humanized immune systems preserve patient tumor heterogeneity and immune microenvironment.
• Multidimensional detection: Integrated flow cytometry (immune cell phenotyping) and multiplex immunohistochemistry (spatial phenotypic analysis) to provide comprehensive pharmacodynamic data.

4、Service Process

• Requirement Communication (1–3 working days) ：Customize model design (target selection, cell source, detection endpoints).
• Model Development (approx. 8 weeks; actual timeline for target humanized mice may vary): Immune cell transplantation / gene editing → Model validation (immune cell reconstitution level ≥ 30%).
• Efficacy Study (6–8 weeks): Drug administration & treatment → In vivo imaging monitoring → Tissue collection and multi-omics analysis.
• Data Delivery (2 weeks): Provide GLP-aligned report including raw data, statistical analysis, and interpretation recommendations.

5、Quality Control and Compliance

• Compliance Standards: All experimental procedures comply with AAALAC animal welfare guidelines and the ISO 9001 quality management system.
• Data Traceability: Electronic laboratory notebooks (ELN system) are used throughout the entire process, supporting raw data review and third-party audits.

6、Case Studies

Case 1: Evaluation of PD-1 Antibody Combination Therapy

• Model: BRGSF-HIS mice implanted with human lung cancer CDX model.
• Results: The combination group achieved a tumor growth inhibition (TGI) rate of 78%, and significantly increased CD8+ T cell infiltration (flow cytometry data showed a 3 fold increase).
• Charts: Tumor growth curve, immune cell infiltration heatmap.

Model experiment flowchart

7、Collaboration Advantages

• Full-cycle Support: One-stop solutions from target validation to IND filing.
• Efficient Delivery: Standardized processes reduce experimental timelines by 30%; urgent projects are prioritized.
• Optimized Costs: Shared model library lowers per-project costs, with phased payment options available.

8、FAQ

• Q:Is a dual humanized model (tumor + immune) supported?

A: Yes! We can simultaneously engraft patient-derived tumor tissue (PDX) and autologous immune cells to highly recapitulate the individualized tumor microenvironment.

• Q:Is data delivery compliant with regulatory requirements?

A: All studies are performed in accordance with GLP-aligned standards, and the data can be directly used for FDA/EMA submissions.

9、Laboratory Highlights

• • SPF Facility: 5,000 cage capacity with dedicated barrier isolation rooms.
  • High-Throughput Platform: Flow cytometer (5-laser configuration), multi-spectral in vivo imaging system.
  • View Full Laboratory Panorama:

View More

10、Contact Us

• Tel: +86 18802035152
• Email: 3691125803@qq.com

Limited-time Offer：

• Free access to the Technical White Paper on Tumor Immune Model Development.
• Book an expert consultation and enjoy 10% off your first order.